Gen-Probe, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$20.0M
Doctors Paid
231
Transactions
1,752
2024 Total
$1.6M
Payment Breakdown by Category
Research$17.8M (89.1%)
Consulting$1.9M (9.7%)
Travel$92,372 (0.5%)
Food & Beverage$31,010 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $17.8M | 791 | 89.1% |
| Consulting Fee | $1.9M | 399 | 9.7% |
| Honoraria | $112,823 | 44 | 0.6% |
| Travel and Lodging | $92,372 | 205 | 0.5% |
| Food and Beverage | $31,010 | 298 | 0.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,801 | 8 | 0.0% |
| Education | $1,686 | 7 | 0.0% |
Payments by Type
Research
$17.8M
791 transactions
General
$2.2M
961 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A10940-SC2/FluP-CSP-02 | $4.8M | 0 | 186 |
| A10109-MGENPS-CSP-01 | $1.8M | 0 | 95 |
| A10810-ATVPS-CSP | $1.8M | 0 | 85 |
| A10924-VAGPS-CSP-01 | $1.6M | 3 | 83 |
| Year 3: Surveillance for Mycoplasma genitalium in US Sexually Transmitted Disease (STD) Clinics | $695,716 | 0 | 11 |
| Year 1: Surveillance for Mycoplasma genitalium in US Sexually Transmitted Disease (STD) Clinics | $623,169 | 0 | 16 |
| Year 2: Surveillance for Mycoplasma genitalium in US Sexually Transmitted Disease (STD) Clinics | $584,278 | 0 | 9 |
| P10934-CMVPS-CSP-01 | $411,444 | 0 | 73 |
| P10940-SC2/FluPF-CSP-01 | $364,975 | 0 | 4 |
| The Stop STDs Study | $316,732 | 0 | 2 |
| 655-A10940-001 | $299,086 | 0 | 32 |
| D0317001 | $286,004 | 0 | 2 |
| Validation of Hologic-Developed Analyte Specific Reagents (ASR) for Detection of Genetic Markers of Macrolide Resistance in Mycoplasma genitalium | $275,867 | 0 | 18 |
| Comparison of nasal swab and nasopharyngeal swab for respiratory testing using Hologic Panther Fusion assay | $230,195 | 0 | 2 |
| Respiratory 4-plex (SARS-CoV-2, Flu A, Flu B, RSV) method comparison and sample procurement study across GenMark ePlex RP2 (ePlex), the BioFire RP2.1 (BF), and Cepheid Xpert Xpress SARS-CoV-2/Flu/RSV test (Xpert). | $228,882 | 0 | 2 |
| 670-P10936-001 | $195,404 | 0 | 16 |
| Quantitative fFN at 36 weeks to Delivery and Quantitative fFn Before Induction: A Feasibility Study | $193,560 | 0 | 2 |
| A10960-SC2P-CSP-01 / A10960-SC2P-CSP-02 | $181,947 | 0 | 13 |
| Method Comparison Study Protocol for the Panther Fusion GI Panels | $171,032 | 0 | 5 |
| ABCTV01-SP-01 | $167,679 | 0 | 21 |
| Prediction of Spontaneous Labor after 39 weeks | $164,869 | 0 | 2 |
| Evaluation of group B Streptococcus and MRSA detection on Panther | $142,446 | 0 | 6 |
| Evaluation of the Panther Fusion Flu A/B/RSV Respiratory Assay Compared to Other Flu/RSV Multiplex Assays in Pediatric Nasopharyngeal Specimens | $142,350 | 0 | 1 |
| Evaluation of the Panther Fusion Flu ABRSV Respiratory Assay Compared to Other Flu RSV Multiplex Assays in Pediatric Nasopharyngeal Specimens | $131,490 | 0 | 1 |
| Performance Evaluation of the Aptima CMV quant Assay in Plasma samples | $121,789 | 0 | 1 |
| V10432-HIVOPS-CSP-02 | $115,576 | 0 | 4 |
| 655-A10960-001 | $109,553 | 0 | 12 |
| Evaluation of the Aptima CMV Quant Assay in Plasma and Non-plasma samples | $100,000 | 0 | 3 |
| Vaginal Fluid Test VF-Test for Prediction of Extremely Preterm Birth after Exam-Indicated Cerclage | $93,221 | 0 | 2 |
| Performance Evaluation of the Aptima CMV quant Assay in Plasma and Non-Plasma samples | $91,933 | 0 | 2 |
Payments by Medical Specialty
Top Paid Doctors — Page 3
| Doctor | Specialty | Location | Total | 2022 |
|---|---|---|---|---|
| Tori O'daniel, Md, MD | Obstetrics & Gynecology | Oklahoma City, OK | $3,627 | $0 |
| Dr. Teresa Alasio, M.d, M.D | Cytopathology | Mount Kisco, NY | $3,550 | $0 |
| Dr. Laura Mckain, Md, MD | Obstetrics & Gynecology | Wilmington, NC | $3,493 | $0 |
| Heather Cugini, M.d, M.D | Obstetrics & Gynecology | Cape Girardeau, MO | $3,439 | $0 |
| Dr. Matthew Hanna, M.d, M.D | Anatomic Pathology & Clinical Pathology | Pittsburgh, PA | $3,406 | $0 |
| Tania Serna, M.d, M.D | Obstetrics & Gynecology | San Francisco, CA | $3,386 | $0 |
| Paul Nyirjesy, Md, MD | Obstetrics & Gynecology | Philadelphia, PA | $3,367 | $0 |
| Dr. Alan Rappleye, M.d, M.D | Obstetrics & Gynecology | Salt Lake City, UT | $3,278 | $0 |
| Ross Miller | Public Health & General Preventive Medicine | Beverly Hills, CA | $3,261 | $0 |
| Dr. Bruce Niebylski, M.d, M.D | Internal Medicine | Detroit, MI | $3,261 | $0 |
| Dr. Janet Mccauley, M.d., M.h.a, M.D., M.H.A | Obstetrics & Gynecology | Durham, NC | $3,261 | $0 |
| Mrs. Stephanie Hack, M.d, M.D | Obstetrics & Gynecology | Washington, DC | $3,238 | $0 |
| Stacy Smith-Foley, Md, MD | Diagnostic Radiology | Little Rock, AR | $3,151 | $0 |
| Eugene Chang, Md, MD | Gynecology | Charleston, SC | $3,115 | $0 |
| Dr. Douglas Richman, Md, MD | Infectious Disease | San Diego, CA | $3,000 | $0 |
| William Cherry, M.d, M.D | Allergy & Immunology | Riverside, CA | $3,000 | $0 |
| Dr. Sean Blackwell, Md, MD | Maternal & Fetal Medicine | Houston, TX | $2,865 | $0 |
| Dr. Heather Brown, M.d, M.D | Anatomic Pathology & Clinical Pathology | Westchester, IL | $2,814 | $0 |
| Dr. Julia Weinberger, M.d, M.D | Critical Care Medicine | Skokie, IL | $2,804 | $0 |
| Errol Norwitz, Md, MD | Maternal & Fetal Medicine | New Haven, CT | $2,783 | $0 |
| Sherie Smalley, M.d, M.D | Anatomic Pathology & Clinical Pathology | West Sacramento, CA | $2,750 | $0 |
| Dr. Renee Allen, M.d, M.D | Obstetrics & Gynecology | Atlanta, GA | $2,717 | $0 |
| Dr. Sandra Aponte, Md, Mba, MD, MBA | Cytopathology | Tampa, FL | $2,687 | $0 |
| Dr. Amitasrigowri Murthy, Md, Mph, MD, MPH | Obstetrics & Gynecology | New York, NY | $2,651 | $0 |
| Adrienne Stevenson, M.d, M.D | Obstetrics & Gynecology | Bel Air, MD | $2,643 | $0 |
Ad
Top Products
- APTIMA $7.8M
- Aptima $5.8M
Associated Products (19)
- APTIMA $8.9M
- Aptima $6.6M
- Panther $3.3M
- PANTHER FUSION $665,388
- Aptima Trichomonas $511,309
- STI $318,392
- Panther Fusion Flu A/B/RSV Assay $302,884
- Rapid fFN $213,450
- FETAL FIBRONECTIN ENZYME IMMUNOASSAY $183,624
- Panther Fusion GBS Assay and Panther Fusion MRSA Assay $142,446
- VF-Test and AF-Test $93,221
- Fetal Fibronectin Enzyme Immunoassay $82,435
- Mycoplasma genitalium $81,333
- Aptima HIV-1 Quant Assay $48,741
- Aptima Candida $36,942
- Panther Fusion Flu A/B/RSVay $34,992
- Aptima Mycoplasma genitalium Assay $29,523
- Aptima Mycoplasma genitalium Assay and Aptima Trichomonas vaginalis Assay $19,632
- Aptima Trichomonas vaginalis Assay $10,969
Payment Categories
- Food & Beverage $31,010
- Consulting $1.9M
- Travel & Lodging $92,372
- Research $17.8M
About Gen-Probe, Inc.
Gen-Probe, Inc. has made $20.0M in payments to 231 healthcare providers, recorded across 1,752 transactions in the CMS Open Payments database. In 2024, the company paid $1.6M. The top product by payment volume is APTIMA ($7.8M).
Payments were distributed across 40 medical specialties. The top specialty by payment amount is Obstetrics & Gynecology ($667,713 to 93 doctors).
Payment categories include: Food & Beverage ($31,010), Consulting ($1.9M), Research ($17.8M), Travel & Lodging ($92,372).
Gen-Probe, Inc. is associated with 19 products in the CMS Open Payments database, including APTIMA, Aptima, and Panther.